Novartis Buys Rights to Experimental MS Drug for $1 Billion

Updated on

Novartis AG agreed to buy the rights to an experimental multiple sclerosis drug from GlaxoSmithKline Plc for as much as $1 billion as it races to catch up with a competing treatment being developed by Roche Holding AG.

To continue reading this article you must be a Bloomberg Professional Service Subscriber.